Yuji Takeda, Tomoyuki Kato, Saima Sabrina, Sei Naito, Hiromi Ito, Naoto Emi, Yuya Kuboki, Yuki Takai, Hiroki Fukuhara, Masaki Ushijima, et al. Intracellular Major Histocompatibility Complex Class II and C-X-C Motif Chemokine Ligand 10-Expressing Neutrophils Indicate the State of Anti-Tumor Activity Induced by Bacillus Calmette-Guérin. Biomedicines. 2023. 11. 11
Shigemitsu Horie, Sei Naito, Shingo Hatakeyama, Shuya Kandori, Kazuyuki Numakura, Renpei Kato, Tomoyuki Koguchi, Shingo Myoen, Yoshihide Kawasaki, Akihiro Ito, et al. Preoperative prognostic model for localized and locally advanced renal cell carcinoma: Michinoku Japan Urological Cancer Study Group. International journal of clinical oncology. 2023
Leandro Blas, Masaki Shiota, Hideaki Miyake, Masayuki Takahashi, Mototsugu Oya, Norihiko Tsuchiya, Naoya Masumori, Hideyasu Matsuyama, Wataru Obara, Nobuo Shinohara, et al. Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiP-RCC study. International Journal of Urology. 2023. 30. 9. 788-796
Leandro Blas, Masaki Shiota, Hideaki Miyake, Masayuki Takahashi, Mototsugu Oya, Norihiko Tsuchiya, Naoya Masumori, Hideyasu Matsuyama, Wataru Obara, Nobuo Shinohara, et al. Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiP-RCC study. International journal of urology : official journal of the Japanese Urological Association. 2023. 30. 9. 788-796
Renpei Kato, Sei Naito, Kazuyuki Numakura, Shingo Hatakeyama, Tomoyuki Koguchi, Takahiro Kojima, Yoshihide Kawasaki, Shuya Kandori, Sadafumi Kawamura, Yoichi Arai, et al. Correction to: Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era - a multi-institutional retrospective study. International journal of clinical oncology. 2023. 28. 5. 726-727
